期刊文献+

TNF-α在IBD发病机制中的调节 被引量:11

Regulatory role of TNF-α in the pathogenesis of IBD
下载PDF
导出
摘要 炎症性肠病(inflammatory bowel disease,IBD)是一种病因不明的肠道非特异性炎症性疾病,包括溃疡性结肠炎和克罗恩病,它们有各自的临床特征,内镜表现和组织学可区分;有学者认为它们是同一疾病的两个不同的阶段。在免疫应答中,TNF-α(TNF核心家族成员之一)作为细胞增殖和凋亡的主要促炎因子,在IBD的发病机制中起重要的调节作用。 Inflammatory bowel disease(IBD),which includes Crohn's disease(CD) and ulcerative colitis(UC),is a uncontrolled inflammatory of the gastrointestinal tract. The etiology is not clear yet.CD and UC have respective clinical features,they could be distinguished with endoscopy and histology.Some studies consider that CD and UC are different stages of development in IBD.In the immune response,TNF-α,as the main pro-inflammatory cytokines of cell proliferation and apoptosis,plays an important role in the regulation of the pathogenesis of IBD.
出处 《胃肠病学和肝病学杂志》 CAS 2011年第2期191-193,共3页 Chinese Journal of Gastroenterology and Hepatology
关键词 TNF-Α 克罗恩病 炎症性肠病 TNF-α Crohn's disease Inflammatory bowel disease
  • 相关文献

参考文献7

二级参考文献74

  • 1Peter Laszlo Lakatos,Laszlo Lakatos,Ferenc Szalay,Claudia Willheim-Polli,Christoph (O|¨)sterreicher,Zsolt Tulassay,Tamas Molnar,Walter Reinisch,Janos Papp,Gyula Mozsik,Hungarian IBD Study Group,Peter Ferenci.Toll-like receptor 4 and NOD2/CARD15 mutations in Hungarian patients with Crohn's disease: Phenotype-genotype correlations[J].World Journal of Gastroenterology,2005,11(10):1489-1495. 被引量:14
  • 2Ilaria Peluso,Francesco Pallone,Giovanni Monteleone.Interleukin-12 and Th1 immune response in Crohn’s disease: Pathogenetic relevance and therapeutic inplication[J].World Journal of Gastroenterology,2006,12(35):5606-5610. 被引量:17
  • 3Andriana C Kaliora,Maria G Stathopoulou,John K Triantafillidis,George VZ Dedoussis,Nikolaos K Andrikopoulos.Chios mastic treatment of patients with active Crohn's disease[J].World Journal of Gastroenterology,2007,13(5):748-753. 被引量:7
  • 4Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF,Ramos R, Britton H, Moran T, Karaliuskas R, Duerr RH,Achkar JP, Brant SR, Bayless TM, Kirschner BS,Hanauer SB, Nunez G, Cho JH. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.Nature, 2001, 411: 603~606.
  • 5Lesage S, Zouali H, Cezard JP, Colombel JF, Belaiche J,Almer S, Tysk C, O'Morain C, Gassull M, Binder V,Finkel Y, Modigliani R, Gower-Rousseau C, Macry J,Merlin F, Chamaill1ard M, Jannot AS, Thomas G, Hugot JP; EPWG-IBD Group; EPIMAD Group; GETAID Group.CARD15/NOD2 mutational analysis and genotypephenotype correlation in 612 patients with inflammatory bowel disease. Am J Hum Genet, 2002, 70: 845~857.
  • 6Noguchi M, Hiwatashi N, Liu Z, Toyota T. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease. Gut, 1998, 43: 203~209.
  • 7Akobeng AK, Zachos M. Tumor necrosis factor-alpha antibody for induction of remission in Crohn's disease.Cochrane Database Syst Rev, 2004, 1: CD003574.
  • 8Rutgeerts P, Van Assche G, Vermeire S. Optimizing antiTNF treatment in inflammatory bowel disease. Gastroenterology, 2004, 126: 1593~1610.
  • 9Powell-Tuck J, Bown RL, Lennard-Jones JE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol, 1978, 13: 833~837.
  • 10Truelove SC, Witts LJ. Cortisone in ulcerative colitis;final report on a therapeutic trial. Br Med J, 1955, 4947:1041~1048.

共引文献57

同被引文献152

引证文献11

二级引证文献71

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部